Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L; BHT-3009 Study Group. Garren H, et al. Among authors: krasulova e. Ann Neurol. 2008 May;63(5):611-20. doi: 10.1002/ana.21370. Ann Neurol. 2008. PMID: 18481290 Clinical Trial.
Corrigendum to 'To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection'[Multiple sclerosis and related disorders vol. 65 (2022) 104014].
Stastna D, Menkyova I, Drahota J, Hrnciarova T, Kubala Havrdova E, Vachova M, Andelova M, Kleinova P, Kovarova I, Krasulova E, Lizrova Preiningerova J, Novakova I, Novotna K, Novotna M, Nytrova P, Pavlickova J, Srpova B, Storey K, Ticha V, Tyblova M, Uher T, Vodehnalova K, Horakova D. Stastna D, et al. Among authors: krasulova e. Mult Scler Relat Disord. 2023 Feb;70:104549. doi: 10.1016/j.msard.2023.104549. Epub 2023 Feb 14. Mult Scler Relat Disord. 2023. PMID: 36796224 Free PMC article. No abstract available.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R. Uher T, et al. Among authors: krasulova e. Mult Scler. 2016 May;22(6):770-81. doi: 10.1177/1352458515601903. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362893 Clinical Trial.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. Kalincik T, et al. Among authors: krasulova e. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. JAMA Neurol. 2023. PMID: 37437240 Free PMC article.
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
Kalincik T, Sharmin S, Roos I, Massey J, Sutton I, Withers B, Freedman MS, Atkins H, Krasulova E, Kubala Havrdova E, Trneny M, Kozak T, Burman J, Macdonell R, Torkildsen Ø, Bø L, Lehmann AK, Sharrack B, Snowden J. Kalincik T, et al. Among authors: krasulova e. J Neurol Neurosurg Psychiatry. 2024 Mar 27:jnnp-2023-332790. doi: 10.1136/jnnp-2023-332790. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38538060
Cerebrospinal fluid biomarkers in multiple sclerosis.
Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK; BioMS Study Group. Tumani H, et al. Neurobiol Dis. 2009 Aug;35(2):117-27. doi: 10.1016/j.nbd.2009.04.010. Epub 2009 May 5. Neurobiol Dis. 2009. PMID: 19426803 Review.
16 results